Related Experiment Video
Updated: May 16, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Similar burden of rare genetic variants in ischemic and non-ischemic dilated cardiomyopathy
Louie Cao1, Joshua Rushakoff1, Ian Williamson1
1Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Insights
Rare disease-causing variants were similarly prevalent in patients with ischemic and non-ischemic dilated cardiomyopathy undergoing heart transplant. Genetic testing may benefit patients with ischemic dilated cardiomyopathy requiring heart transplant.
Area of Science:
- Cardiology
- Genetics
- Genomics
Background:
- Dilated cardiomyopathy (DCM) is a significant cause of heart failure requiring heart transplantation.
- Distinguishing between ischemic and non-ischemic etiologies of DCM is crucial for management.
- The role of rare genetic variants in ischemic DCM is less understood compared to non-ischemic DCM.
Purpose of the Study:
- To determine the prevalence of rare, disease-causing variants in cardiomyopathy-associated genes.
- To compare variant prevalence between patients with ischemic DCM and non-ischemic DCM undergoing heart transplant.
- To assess the potential utility of genetic testing in advanced ischemic heart failure.
Main Methods:
- A single-center cohort study included 60 adult patients undergoing heart transplant for DCM (left ventricular ejection fraction ≤50%).
- Patients were categorized into ischemic DCM (n=16) and non-ischemic DCM (n=44) groups.
- Whole-exome sequencing was performed to identify rare (MAF <0.1%) pathogenic or likely pathogenic variants in cardiomyopathy-associated genes.
Main Results:
- The prevalence of disease-causing variants was similar between ischemic DCM (19%) and non-ischemic DCM (23%) groups.
- In ischemic DCM, variants were identified in TTN and DMD genes.
- In non-ischemic DCM, variants were found in TTN, FLNC, LMNA, MYH7, and RBM20 genes.
Conclusions:
- Patients with ischemic DCM undergoing heart transplant have a comparable burden of rare genetic variants to those with non-ischemic DCM.
- Genetic testing may be beneficial for patients with advanced ischemic heart failure requiring heart transplant.
- These findings highlight the genetic underpinnings of DCM regardless of etiology.
Background:
The aim of the study was to determine the prevalence of rare disease-causing variants in cardiomyopathy-associated genes in a cohort of patients with ischemic and non-ischemic dilated cardiomyopathy undergoing heart transplant.
Methods:
We conducted a single-center cohort study of 60 adult patients with left ventricular ejection fraction ≤50% and left ventricular end-diastolic dimension ≥95th percentile for sex/height who underwent heart transplant between January 2017 and December 2023 and consented to participate in a cardiac tissue biobank. We evaluated the prevalence of rare (minor allele frequency <0.1%) disease-causing (pathogenic or likely pathogenic by American College of Genetics and Genomics criteria) variants in cardiomyopathy-associated genes.
Results:
A total of 60 individuals fulfilled the inclusion criteria: 16 with ischemic dilated cardiomyopathy [88% men, median age 65 years, interquartile range (IQR) 64-68 years] and 44 with non-ischemic dilated cardiomyopathy (80% men, median age 53 years, IQR 39-65 years). We found that the prevalence of disease-causing variants was similar between patients with ischemic dilated cardiomyopathy (3/16 or 19%; 95% credible interval 6%-36%) and those with non-ischemic dilated cardiomyopathy (10/44 or 23%; 95% credible interval 12%-33%). Variants in the ischemic dilated cardiomyopathy group were found in the TTN and DMD genes. Variants in the non-ischemic dilated cardiomyopathy group were found in the TTN, FLNC, LMNA, MYH7, and RBM20 genes.
Conclusions:
Patients with ischemic dilated cardiomyopathy undergoing heart transplant possessed a similar burden of rare disease-causing variants as those with non-ischemic dilated cardiomyopathy. Our results suggest that genetic testing may be beneficial in patients with advanced heart failure requiring heart transplant due to ischemic dilated cardiomyopathy to detect disease-causing variants in cardiomyopathy-associated genes.
More Related Videos
Related Concept Videos
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Pathophysiology of Heart Failure
Pathophysiology of Cardiac Performance
Imaging Studies for Cardiovascular System III: X-Ray
Definition and Purpose
An X-ray, or radiograph, is a non-invasive method that uses ionizing radiation to take images of internal structures. It is mainly used in cardiac imaging to examine the heart, lungs, and major blood vessels, aiming to identify abnormalities in the heart's size, shape, and position, such as heart failure, congenital defects, and vascular...

